相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。NEWLY SYNTHESIZED AMANTADINE DERIVATIVE: SAFETY AND NEUROPHARMACOLOGICAL ACTIVITY
Ivanka Stankova et al.
FARMACIA (2021)
Potential antidepressant effect of amantadine: a review of preclinical studies and clinical trials
Inara F. Raupp-Barcaro et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2018)
Preventive Effect of Two New Neurotensin Analogues on Parkinson's Disease Rat Model
Maria Lazarova et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2018)
Increased Oxidative Stress Markers in Cerebrospinal Fluid from Healthy Subjects with Parkinson's Disease-Associated LRRK2 Gene Mutations
David A. Loeffler et al.
FRONTIERS IN AGING NEUROSCIENCE (2017)
Molecular changes in the postmortem parkinsonian brain
Damien Toulorge et al.
JOURNAL OF NEUROCHEMISTRY (2016)
Antidyskinetic Effect of 7-Nitroindazole and Sodium Nitroprusside Associated with Amantadine in a Rat Model of Parkinson's Disease
Mariza Bortolanza et al.
NEUROTOXICITY RESEARCH (2016)
Hydrogen Sulfide Protects the Brain Against Ischemic Reperfusion Injury in a Transient Model of Focal Cerebral Ischemia
Sevda Gheibi et al.
JOURNAL OF MOLECULAR NEUROSCIENCE (2014)
Pharmacological treatments inhibiting levodopa-induced dyskinesias in MPTP-lesioned monkeys: brain glutamate biochemical correlates
Nicolas Morin et al.
FRONTIERS IN NEUROLOGY (2014)
NMDA antagonists as Parkinson's disease therapy: disseminating the evidence
Zsofia Majlath et al.
NEURODEGENERATIVE DISEASE MANAGEMENT (2014)
Novel nondopaminergic targets for motor features of Parkinson's disease: Review of recent trials
Lorraine V. Kalia et al.
MOVEMENT DISORDERS (2013)
The Pharmacology of L-DOPA-Induced Dyskinesia in Parkinson's Disease
Philippe Huot et al.
PHARMACOLOGICAL REVIEWS (2013)
Targeting Glutamate Receptors to Tackle the Pathogenesis, Clinical Symptoms and Levodopa-Induced Dyskinesia Associated with Parkinson's Disease
Susan Duty
CNS DRUGS (2012)
Glutamate NMDA receptor dysregulation in Parkinson's disease with dyskinesias
Imtiaz Ahmed et al.
BRAIN (2011)
Amantadine attenuates levodopa-induced dyskinesia in mice and rats preventing the accompanying rise in nigral GABA levels
Simone Bido et al.
JOURNAL OF NEUROCHEMISTRY (2011)
Priorities in Parkinson's disease research
Wassilios G. Meissner et al.
NATURE REVIEWS DRUG DISCOVERY (2011)
Oral pelargonidin exerts dose-dependent neuroprotection in 6-hydroxydopamine rat model of hemi-parkinsonism
Mehrdad Roghani et al.
BRAIN RESEARCH BULLETIN (2010)
Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
Elisabeth Wolf et al.
MOVEMENT DISORDERS (2010)
Buspirone improves 6-hydroxydopamine-induced catalepsy through stimulation of nigral 5-HT1A receptors in rats
Alireza M. Nayebi et al.
PHARMACOLOGICAL REPORTS (2010)
Co-administration of the partial dopamine D2 agonist terguride with L-dopa attenuates L-dopa-induced locomotor sensitization in hemiparkinsonian mice
Anti Kalda et al.
BEHAVIOURAL BRAIN RESEARCH (2009)
Pharmacological Modulation of Glutamate Transmission in a Rat Model of L-DOPA-Induced Dyskinesia: Effects on Motor Behavior and Striatal Nuclear Signaling
Daniella Rylander et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2009)
NITRIC OXIDE SYNTHASE INHIBITION ATTENUATES L-DOPA-INDUCED DYSKINESIAS IN A RODENT MODEL OF PARKINSON'S DISEASE
F. E. Padova-Neto et al.
NEUROSCIENCE (2009)
Molecular mechanisms of L-DOPA-induced dyskinesia
Peter Jenner
NATURE REVIEWS NEUROSCIENCE (2008)
The 6-hydroxydopamine model: News from the past
Fabio Blandini et al.
PARKINSONISM & RELATED DISORDERS (2008)
Involvement of the serotonin system in l-dopa-induced dyskinesias
Manolo Carta et al.
PARKINSONISM & RELATED DISORDERS (2008)
The 6-hydroxydopamine model of Parkinson's disease
Nicola Simola et al.
NEUROTOXICITY RESEARCH (2007)
A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia
F Gardoni et al.
JOURNAL OF NEUROSCIENCE (2006)
Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat
C Fiorentini et al.
MOLECULAR PHARMACOLOGY (2006)
Nondopaminergic mechanisms in levodopa-induced dyskinesia
JA Brotchie
MOVEMENT DISORDERS (2005)
Behavioral characterization of a unilateral 6-OHDA-lesion model of Parkinson's disease in mice
R Iancu et al.
BEHAVIOURAL BRAIN RESEARCH (2005)
Motor fluctuations and dyskinesias in Parkinson's disease: clinical manifestations
J Jankovic
MOVEMENT DISORDERS (2005)
Amantadine inhibits NMDA receptors by accelerating channel closure during channel block
TA Blanpied et al.
JOURNAL OF NEUROSCIENCE (2005)
Stiff person syndrome with eye movement abnormality, myasthenia gravis, and thymoma
S Thomas et al.
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY (2005)
Expression of dopamine and vesicular monoamine transporters and differential vulnerability of mesostriatal dopaminergic neurons
T González-Hernández et al.
JOURNAL OF COMPARATIVE NEUROLOGY (2004)
Stages in the development of Parkinson's disease-related pathology
H Braak et al.
CELL AND TISSUE RESEARCH (2004)
Melatonin protects against 6-OHDA-induced neurotoxicity in rats: a role for mitochondrial complex I activity
F Dabbeni-Sala et al.
FASEB JOURNAL (2001)
分享论文
